Japan is seeing broad momentum in both manufacturing and services, alongside rising inflation pressures that keep investors focused on profit growth rather than cheap money. That puts earnings power back in the spotlight. Companies that analysts expect to grow earnings strongly and that also pass basic financial health checks can look especially interesting. This article highlights three stocks from the Healthy high growth potential screener that fit that profile.
The stocks covered below are just a small sample, and the full screen surfaced 1,544 more companies with similarly compelling earnings and financial health stories that are not covered here. To size up that wider opportunity set, head straight to the Healthy high growth potential screener to identify and analyze the highest conviction ideas that fit your own criteria.
Amylyx Pharmaceuticals (AMLX)
Amylyx Pharmaceuticals is a clinical-stage biotech company developing treatments for rare endocrine and neurodegenerative diseases, with its “Healthy high growth potential” link centered on AMX0114 and AMX0035, which target conditions such as ALS and progressive supranuclear palsy. The company is also advancing avexitide and other GLP 1 receptor antagonists for post bariatric hypoglycemia and related disorders. Amylyx Pharmaceuticals currently has a market cap of about US$4.4b.
Investors looking at Amylyx Pharmaceuticals are essentially weighing a high potential growth story against meaningful clinical and financing risk. Positive Phase 3 LUCIDITY data for avexitide in post bariatric hypoglycemia and plans for a 2027 launch have sharpened the earnings growth angle, with analysts also projecting fast revenue expansion if the broader GLP 1 and neurodegeneration pipeline progresses. At the same time, the company still has no material revenue, runs at a loss and has been raising equity, which increases dilution risk. For investors comfortable with early stage biotech risk, the combination of a sizeable cash runway, a differentiated first potential product and multiple shots on goal in rare diseases could make this a company that deserves a closer look.
Accelerating pipeline stories often mask the real crunch point. Before forming a view on Amylyx Pharmaceuticals, review the analyst forecasts for Amylyx Pharmaceuticals and see how that growth narrative lines up with the key risk that has not been fully priced in yet.
Build your own high potential biotech shortlist
Amylyx Pharmaceuticals and the other two stocks here all came from the same Simply Wall St screener, but the real edge is in creating filters that match what matters to you. Use our customizable Screener to mix metrics like future growth, valuation, balance sheet strength and risks, or jump straight into our curated Investing Ideas for ready made starting points.
MercadoLibre (MELI)
MercadoLibre runs a combined e commerce and fintech ecosystem across Brazil, Mexico, Argentina and other Latin American markets, with its Mercado Pago platform, including payments, digital wallets, lending via Mercado Crédito and investing through Mercado Fondo, as the clearest link to the Healthy high growth potential theme. The company reports around US$35.2b in Internet Software & Services revenue and has built this on a broad footprint across Brazil, Mexico, Argentina and other countries, rather than a single country bet. MercadoLibre currently carries a market cap of roughly US$97.4b.
MercadoLibre interests investors who want earnings growth backed by real user adoption rather than just a story. Mercado Pago is expanding across payments, credit and investing, supporting earnings forecasts around 29% a year, while the wider marketplace and logistics businesses keep the ecosystem engaged. At the same time, profit margins have come under pressure as management funds credit growth and AI capabilities. The company also relies on higher risk borrowing rather than customer deposits, which adds funding risk if conditions tighten. The key question is whether this credit engine and 32% forecast ROE justify the premium multiples, or whether the balance between growth and leverage is closer to the edge than it looks at first glance.
MercadoLibre’s credit engine and earnings forecasts could be masking the real story. Use the analyst forecasts for MercadoLibre to see how those projections stack up against the leverage question that few are talking about yet.
Fabrinet (FN)
Fabrinet is a contract manufacturer that helps major equipment makers build high speed optical and electro mechanical components, with its optical transceivers, tunable lasers and transponders for data centers and telecom networks the clearest link to the Healthy high growth potential theme. The company generates all of its US$4.6b in revenue from optical networking equipment and has a global customer base spanning the US, Thailand, China, Japan and other regions. Fabrinet currently has a market cap of about US$15.9b.
Fabrinet gives you direct exposure to the build out of high speed data centers and fiber networks, with record revenue from data center interconnects and next generation transceivers contributing to earnings growth that analysts currently estimate at above 20% a year. At the same time, almost half of revenue is tied to just two customers, and recent capacity expansion means cash flow and margins are under closer watch, as seen in the share price reaction after strong August 2026 results. For investors looking at a financially solid growth company that is closely linked to AI and cloud infrastructure demand, the balance of rapid earnings growth, customer concentration risk and an active capex program makes Fabrinet a story worth examining in more detail.
Fabrinet’s accelerating role in high speed data centers could be only half the story. The real question is how customer concentration and new capex shape that trajectory. Put the pieces together with the analyst forecasts for Fabrinet
Seeking Fresh Alternatives Before They Fly
New breakout ideas rarely stay under the radar for long. Momentum shifts fast, and the best entries often get caught by the crowd. Scan fresh prospects now and act early.
- Spot cash rich companies before momentum headlines hit by running the list of solid balance sheet and fundamentals (50 results) and focus on businesses that already back their story with stronger fundamentals.
- Chase income opportunities that aim to keep payouts flying while prices are still dropping from attention, and filter for consistent yield strength with the 12 dividend fortresses.
- Track early movers in artificial intelligence infrastructure before they move out of reach and surface focused enablers of AI demand through the 55 AI infrastructure stocks.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com